<DOC>
	<DOCNO>NCT02735044</DOCNO>
	<brief_summary>Primary Objective : To compare efficacy HOE901-U300 Lantus term glycated hemoglobin ( HbA1c ) Secondary Objectives : - To compare HOE901-U300 Lantus term : - Percentage patient reach target HbA1c fast plasma glucose ( FPG ) . - To assess safety HOE901-U300 include analysis event hypoglycemia , event hyperglycemia ketosis , development anti-insulin-antibodies .</brief_summary>
	<brief_title>Comparison Safety Efficacy HOE901-U300 With Lantus Children Adolescents With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>The study duration per patient approximately 58 week consist 2 week screening period , 6-month comparative efficacy safety treatment period , 6-month comparative safety extension period , 4-week post treatment follow period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Children adolescents type 1 diabetes mellitus ( T1DM ) least 1 year confirm typical symptom diagnosis and/or antibody test ( presence antiGAD ( glutamic acid decarboxylase ) antiIA2 ( islet antigen 2/tyrosine phosphatase ) antiislet cell antibody ) and/or clinical feature ( eg , history ketoacidosis ) . Signed write informed consent obtain parent ( ) /legal guardian write oral assent obtain patient . Exclusion criterion : Age &lt; 6 year â‰¥18 year randomization . Less 1 year insulin treatment prior screen visit . Less 6 month basal plus mealtime insulin selfmonitoring blood glucose prior screen visit . Patients use premix insulin last 3 month screen visit patient use human regular insulin mealtime insulin last 3 month screen visit . Use insulin pump last 6 month screen visit plan switch pump within next 6 month screen visit . No willingness inject insulin glargine ( Lantus HOE901 [ U300 ] ) daily . HbA1c &lt; 7.5 % &gt; 11 % screening . Initiation glucoselowering medication last 3 month screen visit . Hospitalization care emergency ward diabetic ketoacidosis history severe hypoglycemia ( define need glucagon IV glucose ) accompany seizure and/or unconsciousness and/or coma last 3 month prior screen visit . Postmenarchal girl protect highlyeffective method ( ) birth control and/or unwilling unable test pregnancy . Abstinence sexual intercourse consider acceptable form birth control . Pregnant breastfeeding adolescent , adolescent intend become pregnant study period , risk get pregnant due psychosocial reason study period . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>